Item 1. Financial Statements
113K characters. Original on sec.gov ·
Item 1. Financial Statements
Condensed Consolidated Statements of Earnings
(Unaudited)
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||
| (in millions, except per common share amounts) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
| Revenue | $ | 45,457 | $ | 41,541 | $ | 89,425 | $ | 80,606 | |||||||||||||||
| Cost of products sold | 43,841 | 39,765 | 86,167 | 77,115 | |||||||||||||||||||
| Gross margin | 1,616 | 1,776 | 3,258 | 3,491 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Distribution, selling, general and administrative expenses | 1,151 | 1,147 | 2,265 | 2,284 | |||||||||||||||||||
| Restructuring and employee severance | 7 | 20 | 25 | 57 | |||||||||||||||||||
| Amortization and other acquisition-related costs | 79 | 116 | 158 | 234 | |||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 1,295 | — | 1,293 | 9 | |||||||||||||||||||
| Litigation (recoveries)/charges, net | 34 | 32 | 52 | 1,070 | |||||||||||||||||||
| Operating earnings/(loss) | (950) | 461 | (535) | (163) | |||||||||||||||||||
| Other (income)/expense, net | (13) | (12) | (17) | (19) | |||||||||||||||||||
| Interest expense, net | 37 | 46 | 77 | 91 | |||||||||||||||||||
| Loss on early extinguishment of debt | — | — | 10 | 1 | |||||||||||||||||||
| (Gain)/Loss on sale of equity interest in naviHealth | (1) | — | (1) | — | |||||||||||||||||||
| Earnings/(loss) before income taxes | (973) | 427 | (604) | (236) | |||||||||||||||||||
| Benefit from income taxes | (1,022) | (203) | (925) | (613) | |||||||||||||||||||
| Net earnings | 49 | 630 | 321 | 377 | |||||||||||||||||||
| Less: Net earnings attributable to noncontrolling interests | — | (1) | (1) | (1) | |||||||||||||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 49 | $ | 629 | $ | 320 | $ | 376 | |||||||||||||||
| Earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||||||||||||||
| Basic | $ | 0.17 | $ | 2.14 | $ | 1.13 | $ | 1.28 | |||||||||||||||
| Diluted | 0.17 | 2.13 | 1.12 | 1.27 | |||||||||||||||||||
| Weighted-average number of common shares outstanding: | |||||||||||||||||||||||
| Basic | 279 | 294 | 283 | 293 | |||||||||||||||||||
| Diluted | 281 | 295 | 285 | 295 | |||||||||||||||||||
| Cash dividends declared per common share | $ | 0.4908 | $ | 0.4859 | $ | 0.9816 | $ | 0.9718 |
See notes to condensed consolidated financial statements.
| 26 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||
| (in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
| Net earnings | $ | 49 | $ | 630 | $ | 321 | $ | 377 | |||||||||||||||
| Other comprehensive income/(loss): | |||||||||||||||||||||||
| Foreign currency translation adjustments and other | (18) | 21 | (43) | 33 | |||||||||||||||||||
| Net unrealized gain/(loss) on derivative instruments, net of tax | (6) | 13 | (8) | 18 | |||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | (24) | 34 | (51) | 51 | |||||||||||||||||||
| Total comprehensive income | 25 | 664 | 270 | 428 | |||||||||||||||||||
| Less: comprehensive income attributable to noncontrolling interests | — | (1) | (1) | (1) | |||||||||||||||||||
| Total comprehensive income attributable to Cardinal Health, Inc. | $ | 25 | $ | 663 | $ | 269 | $ | 427 |
See notes to condensed consolidated financial statements.
| 27 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | December 31, 2021 | June 30, 2021 | |||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 3,161 | $ | 3,407 | |||||||
| Trade receivables, net | 9,406 | 9,103 | |||||||||
| Inventories, net | 14,941 | 14,594 | |||||||||
| Prepaid expenses and other | 4,339 | 2,843 | |||||||||
| Assets held for sale | — | 1,101 | |||||||||
| Total current assets | 31,847 | 31,048 | |||||||||
| Property and equipment, net | 2,321 | 2,360 | |||||||||
| Goodwill and other intangibles, net | 8,599 | 10,094 | |||||||||
| Other assets | 913 | 951 | |||||||||
| Total assets | $ | 43,680 | $ | 44,453 | |||||||
| Liabilities and Shareholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 24,759 | $ | 23,700 | |||||||
| Current portion of long-term obligations and other short-term borrowings | 301 | 871 | |||||||||
| Other accrued liabilities | 2,669 | 2,957 | |||||||||
| Liabilities related to assets held for sale | — | 96 | |||||||||
| Total current liabilities | 27,729 | 27,624 | |||||||||
| Long-term obligations, less current portion | 5,342 | 5,365 | |||||||||
| Deferred income taxes and other liabilities | 9,607 | 9,670 | |||||||||
| Shareholders’ equity: | |||||||||||
| Preferred shares, without par value: | |||||||||||
| Authorized—500 thousand shares, Issued—none | — | — | |||||||||
| Common shares, without par value: | |||||||||||
| Authorized—755 million shares, Issued—327 million shares at December 31, 2021 and June 30, 2021 | 2,721 | 2,806 | |||||||||
| Retained earnings | 1,245 | 1,205 | |||||||||
| Common shares in treasury, at cost: 50 million shares and 36 million shares at December 31, 2021 and June 30, 2021, respectively | (2,883) | (2,186) | |||||||||
| Accumulated other comprehensive loss | (85) | (34) | |||||||||
| Total Cardinal Health, Inc. shareholders' equity | 998 | 1,791 | |||||||||
| Noncontrolling interests | 4 | 3 | |||||||||
| Total shareholders’ equity | 1,002 | 1,794 | |||||||||
| Total liabilities and shareholders’ equity | $ | 43,680 | $ | 44,453 |
See notes to condensed consolidated financial statements.
| 28 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)
| Common Shares | Treasury Shares | Accumulated Other Comprehensive Loss | Noncontrolling Interests | Total Shareholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Shares Issued | Amount | Retained Earnings | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended December 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2021 | 327 | $ | 2,666 | $ | 1,335 | (43) | $ | (2,547) | $ | (61) | $ | 3 | $ | 1,396 | |||||||||||||||||||||||||||||||||
| Net earnings | 49 | — | 49 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | (24) | (24) | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 15 | 4 | 19 | |||||||||||||||||||||||||||||||||||||||||||
| Share repurchase program activity | 40 | (7) | (340) | (300) | |||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (139) | (139) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | — | 1 | 1 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2021 | 327 | $ | 2,721 | $ | 1,245 | (50) | $ | (2,883) | $ | (85) | $ | 4 | $ | 1,002 |
| Three Months Ended December 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2020 | 327 | $ | 2,760 | $ | 771 | (33) | $ | (2,022) | $ | (87) | $ | 3 | $ | 1,425 | |||||||||||||||||||||||||||||||||
| Net earnings | 629 | 1 | 630 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 34 | 34 | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 17 | — | 13 | 30 | ||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (144) | (144) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | 1 | (1) | — | — | |||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2020 | 327 | $ | 2,778 | $ | 1,255 | (33) | $ | (2,009) | $ | (53) | $ | 4 | $ | 1,975 |
| Six Months Ended December 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2021 | 327 | $ | 2,806 | $ | 1,205 | (36) | $ | (2,186) | $ | (34) | $ | 3 | $ | 1,794 | |||||||||||||||||||||||||||||||||
| Net earnings | 320 | 1 | 321 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | (51) | (51) | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | (25) | 1 | 43 | 18 | ||||||||||||||||||||||||||||||||||||||||||
| Share repurchase program activity | (60) | (15) | (740) | (800) | |||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (280) | (280) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2021 | 327 | $ | 2,721 | $ | 1,245 | (50) | $ | (2,883) | $ | (85) | $ | 4 | $ | 1,002 |
| Six Months Ended December 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2020 | 327 | $ | 2,789 | $ | 1,170 | (35) | $ | (2,066) | $ | (104) | $ | 3 | $ | 1,792 | |||||||||||||||||||||||||||||||||
| Net earnings | 376 | 1 | 377 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 51 | 51 | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | (11) | 2 | 57 | 46 | ||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (289) | (289) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | (2) | — | (2) | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2020 | 327 | $ | 2,778 | $ | 1,255 | (33) | $ | (2,009) | $ | (53) | $ | 4 | $ | 1,975 |
See notes to condensed consolidated financial statements.
| 29 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Net earnings | $ | 321 | $ | 377 | |||||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 332 | 404 | |||||||||
| (Gain)/Loss on sale of equity interest in naviHealth | (1) | — | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | 1,293 | 9 | |||||||||
| Loss on early extinguishment of debt | 10 | 1 | |||||||||
| Share-based compensation | 42 | 51 | |||||||||
| Provision for bad debts | 25 | 35 | |||||||||
| Change in operating assets and liabilities, net of effects from acquisitions and divestitures: | |||||||||||
| Increase in trade receivables | (329) | (499) | |||||||||
| Increase in inventories | (361) | (1,256) | |||||||||
| Increase in accounts payable | 1,059 | 1,861 | |||||||||
| Other accrued liabilities and operating items, net | (1,842) | 504 | |||||||||
| Net cash provided by operating activities | 549 | 1,487 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Proceeds from divestitures, net of cash transferred, and disposal of property and equipment | 938 | — | |||||||||
| Acquisition of subsidiaries, net of cash acquired | — | (3) | |||||||||
| Additions to property and equipment | (141) | (174) | |||||||||
| Purchases of investments | (4) | (18) | |||||||||
| Proceeds from investments | 22 | 4 | |||||||||
| Net cash provided by/(used in) investing activities | 815 | (191) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Reduction of long-term obligations | (592) | (49) | |||||||||
| Net tax withholdings from share-based compensation | (27) | (6) | |||||||||
| Dividends on common shares | (289) | (289) | |||||||||
| Purchase of treasury shares | (800) | — | |||||||||
| Net cash used in financing activities | (1,708) | (344) | |||||||||
| Effect of exchange rate changes on cash and equivalents | (11) | 14 | |||||||||
| Cash reclassified from assets held for sale | 109 | — | |||||||||
| Net increase/(decrease) in cash and equivalents | (246) | 966 | |||||||||
| Cash and equivalents at beginning of period | 3,407 | 2,771 | |||||||||
| Cash and equivalents at end of period | $ | 3,161 | $ | 3,737 |
See notes to condensed consolidated financial statements.
| 30 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
Notes to Condensed Consolidated Financial Statements
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").
Recently Issued Financial Accounting Standards
Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the six months ended December 31, 2021.
2. Divestitures
In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in Note 6. The Cordis business operated within our Medical segment.
| 31 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
3. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Employee-related | $ | 2 | $ | 8 | |||||||
| Facility exit and other | 5 | 12 | |||||||||
| Total restructuring and employee severance | $ | 7 | $ | 20 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Employee-related | $ | 10 | $ | 32 | |||||||
| Facility exit and other | 15 | 25 | |||||||||
| Total restructuring and employee severance | $ | 25 | $ | 57 |
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.
Restructuring costs during both the three and six months ended December 31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three and six months ended December 31, 2021 also included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
| (in millions) | Employee- Related Costs | Facility Exit and Other Costs | Total | ||||||||||||||
| Balance at June 30, 2021 | $ | 53 | $ | 26 | $ | 79 | |||||||||||
| Additions | 16 | 1 | 17 | ||||||||||||||
| Payments and other adjustments | (25) | (9) | (34) | ||||||||||||||
| Balance at December 31, 2021 | $ | 44 | $ | 18 | $ | 62 |
4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
| (in millions) | Pharmaceutical (1) | Medical (2) | Total | ||||||||||||||
| Balance at June 30, 2021 | $ | 2,659 | $ | 5,330 | $ | 7,989 | |||||||||||
| Goodwill acquired, net of purchase price adjustments | — | — | — | ||||||||||||||
| Foreign currency translation adjustments and other | — | (26) | (26) | ||||||||||||||
| Goodwill impairment | — | (1,307) | (1,307) | ||||||||||||||
| Balance at December 31, 2021 | $ | 2,659 | $ | 3,997 | $ | 6,656 |
(1)At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.
(2)At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $2.7 billion and $1.4 billion, respectively.
During the three months ended December 31, 2021, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment and perform interim goodwill impairment testing for the Medical Unit. This quantitative test resulted in a pre-tax $1.3 billion goodwill impairment charge related to the Medical Unit, which is included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. The goodwill balance of the Medical Unit, after recognizing the impairment, was $2.8 billion at December 31, 2021.
Our determination of estimated fair value of our reporting units is based on a combination of the income-based approach (using a discount rate of 9 percent and a terminal growth rate of 2 percent percent), and the market-based approach. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.
| 32 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
Other Intangible Assets
The following tables summarize other intangible assets by class at:
| December 31, 2021 | |||||||||||||||||||||||
| (in millions) | Gross Intangible | Accumulated Amortization | Net Intangible | Weighted- Average Remaining Amortization Period (Years) | |||||||||||||||||||
| Indefinite-life intangibles: | |||||||||||||||||||||||
| Trademarks and patents | $ | 12 | $ | — | $ | 12 | N/A | ||||||||||||||||
| Total indefinite-life intangibles | 12 | — | 12 | N/A | |||||||||||||||||||
| Definite-life intangibles: | |||||||||||||||||||||||
| Customer relationships | 3,317 | 2,089 | 1,228 | 11 | |||||||||||||||||||
| Trademarks, trade names and patents | 552 | 344 | 208 | 9 | |||||||||||||||||||
| Developed technology and other | 1,036 | 541 | 495 | 9 | |||||||||||||||||||
| Total definite-life intangibles | 4,905 | 2,974 | 1,931 | 10 | |||||||||||||||||||
| Total other intangible assets | $ | 4,917 | $ | 2,974 | $ | 1,943 | N/A |
| June 30, 2021 | |||||||||||||||||
| (in millions) | Gross Intangible | Accumulated Amortization | Net Intangible | ||||||||||||||
| Indefinite-life intangibles: | |||||||||||||||||
| Trademarks and patents | $ | 12 | $ | — | $ | 12 | |||||||||||
| Total indefinite-life intangibles | 12 | — | 12 | ||||||||||||||
| Definite-life intangibles: | |||||||||||||||||
| Customer relationships | 3,330 | 1,989 | 1,341 | ||||||||||||||
| Trademarks, trade names and patents | 551 | 328 | 223 | ||||||||||||||
| Developed technology and other | 1,035 | 506 | 529 | ||||||||||||||
| Total definite-life intangibles | 4,916 | 2,823 | 2,093 | ||||||||||||||
| Total other intangible assets | $ | 4,928 | $ | 2,823 | $ | 2,105 |
Total amortization of intangible assets was $79 million and $113 million for the three months ended December 31, 2021 and 2020, respectively, and $157 million and $228 million for the six months ended December 31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $157 million, $286 million, $262 million, $237 million, and $210 million.
5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt and Other Short-Term Borrowings
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.6 billion and $6.2 billion at December 31, 2021 and June 30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $24.8 billion and $23.7 billion at December 31, 2021 and June 30, 2021, respectively.
During the six months ended December 31, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash.
During the six months ended December 31, 2020, we early repurchased a total of $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt during the six months ended December 31, 2020.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December 31, 2021, we were in compliance with this financial covenant.
| 33 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
6. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.
The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision.
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar year 2017 and 2018 during the six months ended December 31, 2020 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. As a result, as of December 31, 2021, we had an accrual of $20 million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory
requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For
| 34 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Opioid Lawsuits and Investigations
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,400 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
States & Political Subdivisions
Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework").
In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the “Proposed Settlement Agreement”) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals.
The Proposed Settlement Agreement includes a cash component, pursuant to which we would pay up to approximately $6.37 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against us after the Proposed Settlement Agreement becomes effective.
The Proposed Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.
As contemplated under the Proposed Settlement Agreement, in September 2021, the three distributors determined that a sufficient number of states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which was the subdivision sign-on period. The subdivision sign-on period ended January 26, 2022. Each participating state will now make a determination as to whether a sufficient number of its political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. Following that determination by participating states, each of the three distributors will independently determine whether a sufficient number of subdivisions, including both those litigating and those that have not sued, have agreed to participate in the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed to execution. This process is currently contemplated to end in February 2022. The Proposed Settlement Agreement remains subject to contingencies. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.
If the required contingencies are satisfied, the Proposed Settlement Agreement is expected to become effective in April 2022. During the period between the satisfaction of contingencies and the effective date, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Proposed Settlement Agreement in each participating state and dismissing lawsuits of participating states and subdivisions.
In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors have entered into a settlement with each of the states of Florida, New York, Ohio and Rhode Island and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, these states and their participating subdivisions will become a part of it.
West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other
| 35 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
national distributors, entered into a term sheet with the Native American tribes.
A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. Trials are inherently unpredictable and it is possible that the outcome of these trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations.
During the six months ended December 31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68 billion accrued at December 31, 2021, of which $480 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the six months ended December 31, 2020, we recorded total pre-tax charges of $1.02 billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
Department of Justice Investigations
We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.
Private Plaintiffs
The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers,
businesses and individuals alleging personal injury. Private parties had brought approximately 464 lawsuits as of January 25, 2022. Of these, 147 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.
A trial in a case involving 21 plaintiffs is scheduled to begin in state court in Georgia in March 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.
Insurance Litigation
We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (“National Union”) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of December 31, 2021.
Cordis IVC Filter Matters
Product Liability Lawsuits
As of January 25, 2022, we are named as a defendant in 443 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,750 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.
At December 31, 2021, we had a total of $554 million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.09 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
| 36 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
New Mexico Attorney General Action
In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.
SEC Investigation
In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related requests and cannot predict the outcome or duration of the investigation.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them.
Specialty Solutions DOJ Investigation
In November 2018, the United States Attorney’s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $13 million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings during the fiscal year ended June 30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves.
Active Pharmaceutical Ingredient Impurity Litigation
Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product.
In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the “Sartan MDL”) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.
| 37 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
7. Income Taxes
Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Tax Effects of Goodwill Impairment Charge
During the six months ended December 31, 2021, we recognized a $1.3 billion pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $92 million for fiscal 2022.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended December 31, 2021 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2022. Applying the higher tax rate to the current quarter loss resulted in recognizing an interim tax benefit of approximately $1.0 billion, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months and six months ended December 31, 2021 and prepaid expenses and other assets in the condensed consolidated balance sheets at December 31, 2021. This interim tax benefit will reverse in future quarters of fiscal 2022.
Cordis Divestiture
During the six months ended December 31, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $10 million and $19 million during the three and six months ended December 31, 2021, respectively. The tax effects of these matters during the six months ended December 31, 2021 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $38 million.
Tax Effects of Self-Insurance Pre-tax Loss
During the three months ended December 31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The
net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.
Accordingly, our provision for income taxes during the three months ended December 31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.
We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have a current asset on our condensed consolidated balance sheets at December 31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December 31, 2020 related to this matter.
We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.
Tax Effects of Opioid Litigation Charges
In connection with the $1.02 billion pre-tax charges for the opioid litigation recorded during the six months ended December 31, 2020, the net tax benefits were approximately $300 million for the six months ended December 31, 2020 and $228 million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million during the six months ended December 31, 2020, and $219 million for fiscal 2021. We have recognized no tax benefit associated with Opioid accruals made in fiscal 2022.
We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.
Effective Tax Rate
During the three months ended December 31, 2021 and 2020, the effective tax rate was 105.0 percent and (47.6) percent, respectively. The effective tax rate for the three months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual
| 38 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
effective tax rate. The estimated annual effective tax rate for the three months ended December 31, 2020 included the benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the treatment of the tax impacts of the opioid litigation accrual recorded in the prior year.
During the six months ended December 31, 2021 and 2020, the effective tax rate was 153.1 percent and 259.7 percent. The effective tax rate for the six months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The effective tax rate for the six months ended December 31, 2020 included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss and net tax benefit related to the treatment of the tax impacts of opioid litigation charges.
Unrecognized Tax Benefits
We had $937 million and $932 million of unrecognized tax benefits, at December 31, 2021 and June 30, 2021 respectively. The December 31, 2021 and June 30, 2021 balances include $854 million and $849 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At December 31, 2021 and June 30, 2021, we had $45 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million at both December 31, 2021 and June 30, 2021, and is included in other assets in the condensed consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures
and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $3 million at December 31, 2021 and $12 million at June 30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.
8. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
| December 31, 2021 | |||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash equivalents | $ | 1,077 | $ | — | $ | — | $ | 1,077 | |||||||||||||||
| Other investments (1) | 125 | — | — | 125 | |||||||||||||||||||
| Forward contracts (2) | — | 62 | — | 62 | |||||||||||||||||||
| June 30, 2021 | |||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash equivalents | $ | 1,883 | $ | — | $ | — | $ | 1,883 | |||||||||||||||
| Other investments (1) | 126 | — | — | 126 | |||||||||||||||||||
| Forward contracts (2) | — | 42 | — | 42 | |||||||||||||||||||
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated
| 39 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and six months ended December 31, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the six months ended December 31, 2021, we entered into pay-floating interest rate swaps with notional amounts of $100 million and $200 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive income/(loss) were $1 million and $8 million for the three months ended December 31, 2021 and 2020, respectively, and $3 million and $7 million for the six months ended December 31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December 31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $17 million gain and a $27 million loss during the three months ended December 31, 2021 and 2020, respectively, and a $22 million gain and a $52 million loss during the six months ended December 31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5 million during both the three months ended December 31, 2021 and 2020 and $11 million and $10 million during the six months ended December 31, 2021 and 2020, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge
| 40 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $2 million gain and a $4 million loss during the three months ended December 31, 2021 and 2020, respectively, and a $4 million gain and $5 million loss during the six months ended December 31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December 31, 2021 and June 30, 2021 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
| (in millions) | December 31, 2021 | June 30, 2021 | |||||||||
| Estimated fair value | $ | 6,074 | $ | 6,751 | |||||||
| Carrying amount | 5,643 | 6,236 |
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
10. Shareholders' Equity
We repurchased $800 million of our common shares, in the aggregate, through share repurchase programs during the six months ended December 31, 2021. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During the three months ended December 31, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $300 million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares.
During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume
weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
| (in millions) | Foreign Currency Translation Adjustments | Unrealized Gain/(Loss) on Derivatives, net of tax | Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at June 30, 2021 | $ | (46) | $ | 12 | $ | (34) | |||||||||||
| Other comprehensive loss, before reclassifications | (43) | (5) | (48) | ||||||||||||||
| Amounts reclassified to earnings | — | (3) | (3) | ||||||||||||||
| Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax | (43) | (8) | (51) | ||||||||||||||
| Balance at December 31, 2021 | $ | (89) | $ | 4 | $ | (85) |
11. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Weighted-average common shares–basic | 279 | 294 | |||||||||
| Effect of dilutive securities: | |||||||||||
| Employee stock options, restricted share units and performance share units | 2 | 1 | |||||||||
| Weighted-average common shares–diluted | 281 | 295 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Weighted-average common shares–basic | 283 | 293 | |||||||||
| Effect of dilutive securities: | |||||||||||
| Employee stock options, restricted share units and performance share units | 2 | 2 | |||||||||
| Weighted-average common shares–diluted | 285 | 295 |
The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were 5 million during both the three and six months ended December 31, 2021 and 4 million during both the three months and the six months ended December 31, 2020.
| 41 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
12. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 41,164 | $ | 37,040 | |||||||
| Nuclear and Precision Health Solutions | 211 | 196 | |||||||||
| Pharmaceutical segment revenue | 41,375 | 37,236 | |||||||||
| Medical distribution and products (3) | 3,446 | 3,729 | |||||||||
| Cardinal Health at-Home Solutions | 639 | 581 | |||||||||
| Medical segment revenue | 4,085 | 4,310 | |||||||||
| Total segment revenue | 45,460 | 41,546 | |||||||||
| Corporate (4) | (3) | (5) | |||||||||
| Total revenue | $ | 45,457 | $ | 41,541 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 80,778 | $ | 71,956 | |||||||
| Nuclear and Precision Health Solutions | 419 | 392 | |||||||||
| Pharmaceutical segment revenue | 81,197 | 72,348 | |||||||||
| Medical distribution and products (3) | 7,013 | 7,167 | |||||||||
| Cardinal Health at-Home Solutions | 1,221 | 1,100 | |||||||||
| Medical segment revenue | 8,234 | 8,267 | |||||||||
| Total segment revenue | 89,431 | 80,615 | |||||||||
| Corporate (4) | (6) | (9) | |||||||||
| Total revenue | $ | 89,425 | $ | 80,606 |
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following tables present revenue by geographic area:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| United States | $ | 44,382 | $ | 40,360 | |||||||
| International | 1,078 | 1,186 | |||||||||
| Total segment revenue | 45,460 | 41,546 | |||||||||
| Corporate (1) | (3) | (5) | |||||||||
| Total revenue | $ | 45,457 | $ | 41,541 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| United States | $ | 87,223 | $ | 78,336 | |||||||
| International | 2,208 | 2,279 | |||||||||
| Total segment revenue | 89,431 | 80,615 | |||||||||
| Corporate (1) | (6) | (9) | |||||||||
| Total revenue | $ | 89,425 | $ | 80,606 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation
| 42 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
-
last-in first-out, or ("LIFO"), inventory charges/(credits);
-
surgical gown recall costs/(income);
-
restructuring and employee severance;
-
amortization and other acquisition-related costs;
-
impairments and (gain)/loss on disposal of assets;
-
litigation (recoveries)/charges, net;
-
state opioid assessment related to prior fiscal years;
-
other (income)/expense, net;
-
interest expense, net;
-
loss on early extinguishment of debt;
-
(gain)/loss on sale of equity interest in naviHealth; or
-
provision for income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $11 million and $6 million for the three months ended December 31, 2021 and 2020, and $18 million and $11 million for the six months ended December 31, 2021 and 2020, respectively.
In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in Note 4, we recognized a $1.3 billion goodwill impairment charge during the three and six months ended December 31, 2021 which was retained at Corporate.
In connection with the opioid litigation as discussed further in Note 6, we recognized a pre-tax charge of $1.02 billion during the six months ended December 31, 2020 which was retained at Corporate.
The following tables present segment profit by reportable segment and Corporate:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Pharmaceutical (1) | $ | 426 | $ | 413 | |||||||
| Medical | 50 | 236 | |||||||||
| Total segment profit | 476 | 649 | |||||||||
| Corporate | (1,426) | (188) | |||||||||
| Total operating earnings/(loss) | $ | (950) | $ | 461 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Pharmaceutical (1) | $ | 832 | $ | 815 | |||||||
| Medical | 173 | 466 | |||||||||
| Total segment profit | 1,005 | 1,281 | |||||||||
| Corporate | (1,540) | (1,444) | |||||||||
| Total operating loss | $ | (535) | $ | (163) |
(1)Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
The following table presents total assets for each reportable segment and Corporate at:
| (in millions) | December 31, 2021 | June 30, 2021 | |||||||||
| Pharmaceutical | $ | 24,427 | $ | 23,624 | |||||||
| Medical (1) (2) | 12,737 | 15,408 | |||||||||
| Corporate | 6,516 | 5,421 | |||||||||
| Total assets | $ | 43,680 | $ | 44,453 |
(1)Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.
(2)Medical reflects a $1.3 billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.
13. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
| Three Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Restricted share unit expense | $ | 17 | $ | 17 | |||||||
| Performance share unit expense | 1 | 6 | |||||||||
| Total share-based compensation | $ | 18 | $ | 23 |
| Six Months Ended December 31, | |||||||||||
| (in millions) | 2021 | 2020 | |||||||||
| Restricted share unit expense | $ | 35 | $ | 36 | |||||||
| Performance share unit expense | 7 | 15 | |||||||||
| Total share-based compensation | $ | 42 | $ | 51 |
The total tax benefit related to share-based compensation was $2 million and $3 million for the three months ended December 31, 2021 and 2020, and $6 million and $7 million for the six months ended December 31, 2021 and 2020, respectively.
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
| 43 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |
| Notes to Financial Statements |
The following table summarizes all transactions related to restricted share units under the Plans:
| (in millions, except per share amounts) | Restricted Share Units | Weighted-Average Grant Date Fair Value per Share | |||||||||
| Nonvested at June 30, 2021 | 3 | $ | 49.05 | ||||||||
| Granted | 2 | 51.62 | |||||||||
| Vested | (2) | 49.47 | |||||||||
| Canceled and forfeited | — | — | |||||||||
| Nonvested at December 31, 2021 | 3 | $ | 45.66 |
At December 31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.
Stock Options
Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
The following table summarizes all stock option transactions under the Plans:
| (in millions, except per share amounts) | Stock Options | Weighted-Average Exercise Price per Common Share | |||||||||
| Outstanding at June 30, 2021 | 4 | $ | 68.46 | ||||||||
| Granted | — | — | |||||||||
| Exercised | — | — | |||||||||
| Canceled and forfeited | — | — | |||||||||
| Outstanding at December 31, 2021 | 4 | $ | 69.24 | ||||||||
| Exercisable at December 31, 2021 | 4 | $ | 69.41 |
At December 31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years.
The following tables provide additional detail related to stock options:
| (in millions) | December 31, 2021 | June 30, 2021 | |||||||||
| Aggregate intrinsic value of outstanding options at period end | $ | 3 | $ | 11 | |||||||
| Aggregate intrinsic value of exercisable options at period end | 3 | 11 |
| (in years) | December 31, 2021 | June 30, 2021 | |||||||||
| Weighted-average remaining contractual life of outstanding options | 4 | 4 | |||||||||
| Weighted-average remaining contractual life of exercisable options | 4 | 4 |
Performance Share Units
Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
| (in millions, except per share amounts) | Performance Share Units | Weighted-Average Grant Date Fair Value per Share | |||||||||
| Nonvested at June 30, 2021 | 1.2 | $ | 54.89 | ||||||||
| Granted | 0.4 | 51.91 | |||||||||
| Vested | (0.3) | 52.36 | |||||||||
| Canceled and forfeited | (0.1) | 52.84 | |||||||||
| Nonvested at December 31, 2021 | 1.2 | $ | 52.99 |
At December 31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.
| 44 | Cardinal Health | Q2 Fiscal 2022 Form 10-Q |